Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2

Bavec, Aljoša (author)

Glucagon-like peptide-1 (GLP-1) based therapy is well established for treating diabetes mellitus type 2. Moreover, GLP-1 receptor agonists influence weight loss, and have potential for treating obesity. GLP-1 receptor agonists should be administered in low doses, together with drugs that potentiate insulin release, to avoid some minor side effects. We have focused on incretin hormones, especially GLP-1 and its analogues. Here we discuss the effect of the third intracellular loop-derived peptide of GLP-1 receptor on intracellular mono-ADP-ribosyltransferase and its role in regulating the receptor. We suggest that this intracellular mono-ADP-ribosyltransferase could constitute a possible novel pharmacological target in the treatment of diabetes mellitus type 2 and obesity.

• Language: English
• Keywords: diabetes mellitus type 2, glucagon, obesity
• Work type: Not categorized (r6)
• Tipology: 1.02 - Review Article
• Organization: MF - Faculty of Medicine
• Year: 2013
• Number of pages: str. 237-242
• Numbering: Vol. 60, no. 2
• UDC: 616.379
• ISSN on article: 1318-0207
• COBISS.SI-ID: 30773209
• Average score: (0 votes)
• Your score: Voting is allowed only to logged in users.

Record is a part of a journal

• Title: Acta chimica slovenica
• Shortened title: Acta chim. slov.
• Publisher: Slovensko kemijsko društvo, =Slovenian Chemical Society
• ISSN: 1318-0207
• COBISS.SI-ID: 14086149

Secondary language

• Language: Slovenian
• Keywords: sladkorna bolezen tip 2, glukagon, debelost